Urol Oncol 2012,30(2):177–181 PubMedCrossRef 15 Yates DR, Rehman

Urol Oncol 2012,30(2):177–181.PubMedCrossRef 15. Yates DR, Rehman I, check details Abbod MF, Meuth M, Cross SS, Linkens DA, et al.: Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007,13(7):2046–2053.PubMedCrossRef 16. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G: Relative quantification

of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002,30(12):e57.PubMedCrossRef 17. Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, et al.: Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 2005,33(14):e128.PubMedCrossRef 18. Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S, et al.: Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med 2010, 8:86.PubMedCrossRef 19. Leong KJ, Wei W, Tannahill LA, Caldwell GM, Jones CE, Morton DG, et al.: Methylation profiling of rectal cancer identifies novel markers of early-stage disease. Br J Surg 2011,98(5):724–734.PubMedCrossRef

20. Moelans CB, Verschuur-Maes AH, Van Diest PJ: Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol 2011,225(2):222–231.PubMedCrossRef 21. Pavicic W, Perkiö E, Kaur S, Peltomäki P: Altered methylation at microRNA-associated BI-D1870 research buy CpG islands in hereditary and sporadic carcinomas: a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)-based approach. Mol Med 2011,17(7–8):726–735.PubMed 22. Joensuu

EI, Abdel-Rahman WM, Ollikainen M, Ruosaari S, Knuutila S, Peltomäki P: Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Cancer Res 2008,68(12):4597–4605.PubMedCrossRef 23. Fleuriel C, Touka M, Boulay G, Guérardel C, Rood BR, Leprince D: HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors. Int J Biochem Cell Biol 2009,41(1):26–33.PubMedCrossRef see more 24. Pljesa-Ercegovac M, Savic-Radojevic A, Dragicevic D, Mimic-Oka J, Matic M, Sasic T, Pekmezovic T: Enhanced GSTP1 expression in VRT752271 manufacturer transitional cell carcinoma of urinary bladder is associated with altered apoptotic pathways. Urol Oncol 2011,29(1):70–77.PubMedCrossRef 25. Ha YS, Jeong P, Kim JS, Kwon WA, Kim IY, Yun SJ: Tumorigenic and prognostic significance of RASSF1A expression in Low-grade (WHO grade 1 and grade 2) nonmuscle-invasive bladder cancer. Urology 2012,79(6):e1-e6. 1411PubMedCrossRef 26. Kim YK, Kim WJ: Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol 2009,16(1):17–22.PubMedCrossRef 27. Serizawa RR, Ralfkiaer U, Steven K, Lam GW, Schmiedel S, Schüz J, et al.: Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>